Suppr超能文献

干细胞移植前铁蛋白水平对移植后期并发症的影响:一项旨在确定铁过载对移植后期结局潜在作用的分析。

The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes.

作者信息

Efebera Yvonne A, Thandi Rupinderjit S, Saliba Rima M, Popat Uday, De Lima Marcos, Alousi Amin, Hosing Chitra, Rondon Gabriela, Champlin Richard, Giralt Sergio

机构信息

Department of Stem Cell Transplantation and Cellular Therapies, University of Texas M.D. Anderson Cancer Center, Houston, TX.

出版信息

Internet J Hematol. 2009;7(1).

Abstract

BACKGROUND

Iron overload has been associated with increased non-relapse mortality (NRM) in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing hematopoietic stem cell transplantation (HSCT). Elevated ferritin level pre-HSCT has been used as a marker for iron overload. It is unclear whether the negative effect of iron overload as measured by elevated ferritin level extends beyond the first three months post HSCT, as this would suggest a potential role for active management of iron overload post HSCT.

PATIENTS

Sixty-three patients with AML and MDS who underwent an allogeneic HSCT from a sibling or unrelated donor between January to December 2006, had a pre-HSCT ferritin level and were alive and disease free 90 days post HSCT.

RESULTS

Median age was 51. Patients with the lowest pre-HSCT ferritin level (Q1) had a trend towards improved overall survival and progression free survival when compared to patients with higher level (Q2-Q4) (P=0.06, and 0.125). Cumulative incidence of NRM at 2 years was 20 and 30% respectively (P=0.4).

CONCLUSION

Pre-HSCT ferritin level may still have an impact on HSCT events beyond 3 months post transplant, suggesting a role for research into active management of iron overload with either phlebotomy or chelation.

摘要

背景

铁过载与接受造血干细胞移植(HSCT)的急性髓系白血病(AML)和骨髓增生异常综合征(MDS)患者非复发死亡率(NRM)增加有关。HSCT前铁蛋白水平升高已被用作铁过载的标志物。目前尚不清楚,以铁蛋白水平升高衡量的铁过载的负面影响是否会在HSCT后三个月以上持续存在,因为这可能提示HSCT后积极管理铁过载具有潜在作用。

患者

63例AML和MDS患者于2006年1月至12月间接受了来自同胞或无关供体的异基因HSCT,HSCT前有铁蛋白水平记录,且HSCT后90天存活且无疾病。

结果

中位年龄为51岁。与铁蛋白水平较高(Q2-Q4)的患者相比,HSCT前铁蛋白水平最低(Q1)的患者总生存期和无进展生存期有改善趋势(P = 0.06和0.125)。2年时NRM的累积发生率分别为20%和30%(P = 0.4)。

结论

HSCT前铁蛋白水平可能在移植后3个月以上仍对HSCT相关事件有影响,提示对采用放血或螯合疗法积极管理铁过载进行研究具有一定作用。

相似文献

5
6
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.
Biol Blood Marrow Transplant. 2011 Jun;17(6):852-60. doi: 10.1016/j.bbmt.2010.09.006. Epub 2010 Sep 18.
8
Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation.
Transplant Proc. 2010 Jun;42(5):1841-8. doi: 10.1016/j.transproceed.2009.11.049.

引用本文的文献

本文引用的文献

2
The transplant iron score as a predictor of stem cell transplant survival.
J Hematol Oncol. 2009 Oct 24;2:44. doi: 10.1186/1756-8722-2-44.
7
Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation.
Bone Marrow Transplant. 2008 Dec;42(12):799-805. doi: 10.1038/bmt.2008.262. Epub 2008 Sep 1.
8
High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors.
Biol Blood Marrow Transplant. 2008 Jul;14(7):790-4. doi: 10.1016/j.bbmt.2008.04.009.
10
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.
Biol Blood Marrow Transplant. 2008 Jan;14(1):28-35. doi: 10.1016/j.bbmt.2007.07.016. Epub 2007 Nov 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验